



## Oesophageal Adenocarcinoma

Guest Editor:

**Dr. Matthias Reeh**

Department of General, Visceral  
and Thoracic Surgery, University  
Medical Center, Hamburg-  
Eppendorf, Martinistrasse 52,  
20246 Hamburg, Germany

Deadline for manuscript  
submissions:

**closed (18 October 2022)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue is about Oesophageal adenocarcinoma (OEA). OEA is among the most lethal conditions gastroenterologists face today, with only 16% of patients surviving 5 years and a median survival time of less than 1 year. Unfortunately, little progress has been made in improving survival and patients' outcome. Oesophageal adenocarcinoma usually presents at a late stage, with most patients presenting with T3 or T4 disease and, thus, high mortality rates. Very few treatment regimens are available. What is more, the incidence of OEA has increased in the last 40 years, by approximately 600% from the 1970s. The reasons for this increase and tumor biology in particular are poorly understood. Treatment of OEA has evolved in recent years, with several new treatment techniques that lead to improvements in oncology, gastroenterology, and surgery. However, recent studies have shown that we are still far away from a clear understanding of oesophageal adenocarcinoma.

Here, we welcome papers outlining tumor biology, diagnostics, and treatment modalities of Oesophageal adenocarcinoma.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)